Value of antiplatelets in the spotlight for secondary prevention

By  

Inpharma, Vol. 1, Iss. 1618, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke

By Ringleb Peter A   Schwark Christian   Schwaninger Markus   Schellinger Peter D  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 3, 2005-03 ,pp. : 359-367

Informa Healthcare

Access to resources Recommend Favorite

Atorvastatin best value for money for secondary CHD prevention

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 408-409, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Spotlight on Ramipril in the Prevention of Cardiovascular Outcomes

By Warner G.T.   Perry C.M.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 2, 2003-01 ,pp. : 113-116

Adis International

Access to resources Recommend Favorite

The UK's proposed value-based pricing under the spotlight

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 636, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite